<DOC>
	<DOCNO>NCT01002417</DOCNO>
	<brief_summary>The hypothesis study examine whether MCS-2 safe effective treatment low urinary tract symptom suggestive benign prostatic hyperplasia .</brief_summary>
	<brief_title>MCS Treatment Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>This adaptive trial design , combines element Phase 2b ( dose range ) study Phase 3 ( hypothesis test ) study , objectives two phase separate . Phase 2b Objectives : The primary objective Phase 2b portion study evaluate , treatment-naïve population , 0 mg ( placebo ) , 15 mg , 30 mg MCS-2 term dose response determine optimal dose use Phase 3 portion trial . The secondary objective portion study evaluate safety tolerability 15 mg 30 mg MCS-2 . Phase 3 Objectives : The primary objective Phase 3 portion study evaluate , treatment-naïve population , effectiveness MCS-2 ( dosage determine Phase 2b portion study ) , compare MCS placebo ( 0 mg ) , reduce low urinary tract symptom ( LUTS ) suggestive benign prostatic hyperplasia ( BPH ) . The secondary objective study evaluate safety tolerability MCS-2 ( dosage determine Phase 2b portion study ) , compare MCS placebo ( 0 mg ) .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Age ≧ 40 year old Not treat BPH LUTS PSA ≦ 4 ng/ml pathologicallyproven prostate cancer IPSS ≥ 10 No known malignancy AST/ALT ≦ 3X UNL Creatinine ≦ 3X UNL Subjects sign inform consent form Subjects ' LUTS BPHrelated Have treat pelvis irradiation pelvic surgery Plan undergo invasive procedure within study period Active infection inflammation Considered ineligible investigator</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Multi-carotenoids</keyword>
	<keyword>MCS-2</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>International prostate symptom score</keyword>
</DOC>